Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. (Q53359900)

13 May 2018

title

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. (English)

1 reference

13 May 2018

1 reference

1

1 reference

13 May 2018

author name string

E S Newlands

2

1 reference

13 May 2018

L Holden

3

1 reference

13 May 2018

G J Rustin

4

1 reference

13 May 2018

R H Begent

5

1 reference

13 May 2018

publication date

1 May 1997

1 reference

13 May 2018

published in

Annals of Oncology

1 reference

13 May 2018

volume

8

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

477-483

1 reference

13 May 2018

The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Phase II Trial of High-Dose Carboplatin and Etoposide With Autologous Bone Marrow Transplantation in First-Line Therapy for Patients With Poor-Risk Germ Cell Tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Further advances in the management of malignant teratomas of the testis and other sites

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Successful management of metastatic and primary germ cell tumors in the brain

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Long-Term Outcome of Patients with Relapsed and Refractory Germ Cell Tumors Treated with High-Dose Chemotherapy and Autologous Bone Marrow Rescue

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Pulmonary emboli as a complication of germ cell cancer treatment.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Evaluation of long-term toxicity after chemotherapy for testicular cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Secondary tumours following etoposide containing therapy for germ cell cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Two different classes of therapy-related and de-novo acute myeloid leukemia?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Hematologic neoplasia associated with primary mediastinal germ-cell tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Secondary neoplasms following treatment of malignant germ cell tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279222625

7 January 2021

Identifiers

DOI

10.1023/A:1008279222625

1 reference

13 May 2018

1 reference

13 May 2018